Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

Science Translational Medicine

Volumn 6, Issue 224, 2014, Pages

  Davila, Marco L ^a   Riviere, Isabelle ^a   Wang, Xiuyan ^a   Bartido, Shirley ^a   Park, Jae ^a   Curran, Kevin ^a   Chung, Stephen S ^a   Stefanski, Jolanta ^a   Borquez Ojeda, Oriana ^a   Olszewska, Malgorzata ^a   Qu, Jinrong ^a   Wasielewska, Teresa ^a   He, Qing ^a   Fink, Mitsu ^a   Shinglot, Himaly ^a   Youssif, Maher ^a   Satter, Mark ^a   Wang, Yongzeng ^a   Hosey, James ^a   Quintanilla, Hilda ^a   Halton, Elizabeth ^a   Bernal, Yvette ^a   Bouhassira, Diana C G ^a   Arcila, Maria E ^a   Gonen, Mithat ^a   Roboz, Gail J ^b   Maslak, Peter ^a   Douer, Dan ^a   Frattini, Mark G ^b   Giralt, Sergio ^a   Sadelain, Michel ^a   Brentjens, Renier ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Leukemia Service   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; CYTOKINE; TOCILIZUMAB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; MIDDLE AGED; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; T LYMPHOCYTE; THERAPY EFFECT; YOUNG ADULT;

ADOLESCENT; ADULT; CELL TRANSPLANTATION; FEMALE; HUMANS; IMMUNOTHERAPY; LEUKEMIA, B-CELL; MALE; MIDDLE AGED; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84896335556     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3008226     Document Type: Article

References (29)

1. R. J. Brentjens, M. L. Davila, I. Riviere, J. Park, X. Wang, L. G. Cowell, S. Bartido, J. Stefanski, C. Taylor, M. Olszewska, O. Borquez-Ojeda, J. Qu, T. Wasielewska, Q. He, Y. Bernal, I. V. Rijo, C. Hedvat, R. Kobos, K. Curran, P. Steinherz, J. Jurcic, T. Rosenblat, P. Maslak, M. Frattini, M. Sadelain, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapyrefractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).
2. S. A. Grupp, M. Kalos, D. Barrett, R. Aplenc, D. L. Porter, S. R. Rheingold, D. T. Teachey, A. Chew, B. Hauck, J. F. Wright, M. C. Milone, B. L. Levine, C. H. June, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518 (2013).
3. J. N. Kochenderfer, M. E. Dudley, S. A. Feldman, W. H. Wilson, D. E. Spaner, I. Maric, M. Stetler-Stevenson, G. Q. Phan, M. S. Hughes, R. M. Sherry, J. C. Yang, U. S. Kammula, L. Devillier, R. Carpenter, D. A. Nathan, R. A. Morgan, C. Laurencot, S. A. Rosenberg, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709-2720 (2012).
4. M. Sadelain, R. Brentjens, I. Rivière, The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388-398 (2013).
5. M. L. Davila, R. Brentjens, X. Wang, I. Rivière, M. Sadelain, How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology 1, 1577-1583 (2012).
6. R. J. Brentjens, I. Rivière, J. H. Park, M. L. Davila, X. Wang, J. Stefanski, C. Taylor, R. Yeh, S. Bartido, O. Borquez-Ojeda, M. Olszewska, Y. Bernal, H. Pegram, M. Przybylowski, D. Hollyman, Y. Usachenko, D. Pirraglia, J. Hosey, E. Santos, E. Halton, P. Maslak, D. Scheinberg, J. Jurcic, M. Heaney, G. Heller, M. Frattini, M. Sadelain, Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817-4828 (2011).
7. M. Kalos, B. L. Levine, D. L. Porter, S. Katz, S. A. Grupp, A. Bagg, C. H. June, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).
8. A. K. Fielding, S. M. Richards, R. Chopra,H.M. Lazarus, M. R. Litzow, G. Buck, I. J.Durrant, S. M. Luger, D. I. Marks, I. M. Franklin, A. K. McMillan, M. S. Tallman, J. M. Rowe, A. H. Goldstone; Medical Research Council of the United Kingdom Adult ALL Working Party; Eastern Cooperative Oncology Group, Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109, 944-950 (2007).
9. N. Gökbuget, D. Stanze, J. Beck, H. Diedrich, H. A. Horst, A. Hüttmann, G. Kobbe, K. A. Kreuzer, L. Leimer, A. Reichle, M. Schaich, S. Schwartz, H. Serve, M. Starck, M. Stelljes, R. Stuhlmann, A. Viardot, K. Wendelin, M. Freund, D. Hoelzer; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia, Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 120, 2032-2041 (2012).
10. S. O'Brien, G. Schiller, J. Lister, L. Damon, S. Goldberg, W. Aulitzky, D. Ben-Yehuda, W. Stock, S. Coutre, D. Douer, L. T. Heffner, M. Larson, K. Seiter, S. Smith, S. Assouline, P. Kuriakose, L.Maness, A. Nagler, J. Rowe, M. Schaich, O. Shpilberg, K. Yee, G. Schmieder, J. A. Silverman, D. Thomas, S. R. Deitcher, H. Kantarjian, High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J. Clin. Oncol. 31, 676-683 (2013).
11. H. Robins, Immunosequencing: Applications of immune repertoire deep sequencing. Curr. Opin. Immunol. 25, 646-652 (2013).
12. M. B. Pepys, G. M. Hirschfield, C-reactive protein: A critical update. J. Clin. Invest. 111, 1805-1812 (2003).
13. D. A. Thomas, H. Kantarjian, T. L. Smith, C. Koller, J. Cortes, S. O'Brien, F. J. Giles, J. Gajewski, S. Pierce, M. J. Keating, Primary refractory and relapsed adult acute lymphoblastic leukemia: Characteristics, treatment results, and prognosis with salvage therapy. Cancer 86, 1216-1230 (1999).
14. J. D. Goldberg, A. Linker, D. Kuk, R. Ratan, J. Jurcic, J. N. Barker, H. Castro-Malaspina, S. Giralt, K. Hsu, A. A. Jakubowski, R. Jenq, G. Koehne, E. B. Papadopoulos,M. R. van den Brink, J. W. Young, F. Boulad, N. A. Kernan, R. J. O'Reilly, S. E. Prockop, J. Yahalom, G. Heller, M. A. Perales, T cell- depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: Longterm survival for patients in first complete remission with a decreased risk of graft-versus-host disease. Biol. Blood Marrow Transplant. 19, 208-213 (2013).
15. A. Oriol, S. Vives, J. M. Hernández-Rivas, M. Tormo, I. Heras, C. Rivas, C. Bethencourt, F. Moscardó, J. Bueno, C. Grande, E. del Potro, R. Guardia, S. Brunet, J. Bergua, T. Bernal, M. J. Moreno, C. Calvo, P. Bastida, E. Feliu, J. M. Ribera; Programa Español de Tratamiento en Hematologia Group, Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 95, 589-596 (2010).
16. D. L. Porter, B. L. Levine, M. Kalos, A. Bagg, C. H. June, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
17. M. C. Milone, J. D. Fish, C. Carpenito, R. G. Carroll, G. K. Binder, D. Teachey, M. Samanta, M. Lakhal, B. Gloss, G. Danet-Desnoyers, D. Campana, J. L. Riley, S. A. Grupp, C. H. June, Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453-1464 (2009).
18. J. N. Kochenderfer, W. H. Wilson, J. E. Janik, M. E. Dudley, M. Stetler-Stevenson, S. A. Feldman, I. Maric, M. Raffeld, D. A. Nathan, B. J. Lanier, R. A. Morgan, S. A. Rosenberg, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099-4102 (2010).
19. S. J. van der Stegen, D. M. Davies, S. Wilkie, J. Foster, J. K. Sosabowski, J. Burnet, L. M. Whilding, R. M. Petrovic, S. Ghaem-Maghami, S. Mather, J. P. Jeannon, A. C. Parente-Pereira, J. Maher, Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: Identifying a window of therapeutic opportunity? J. Immunol. 191, 4589-4598 (2013).
20. D. T. Teachey, S. R. Rheingold, S. L. Maude, G. Zugmaier, D. M. Barrett, A. E. Seif, K. E. Nichols, E. K. Suppa, M. Kalos, R. A. Berg, J. C. Fitzgerald, R. Aplenc, L. Gore, S. A. Grupp, Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121, 5154-5157 (2013).
21. G. Suntharalingam, M. R. Perry, S.Ward, S. J. Brett, A. Castello-Cortes, M. D. Brunner, N. Panoskaltsis, Cytokine storm in a phase 1 trial of the anti-CD28monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006).
22. M. L. Davila, C. C. Kloss, G. Gunset, M. Sadelain, CD19 CAR-targeted T cells induce longterm remission and B cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLOS One 8, e61338 (2013).
23. D. Hollyman, J. Stefanski, M. Przybylowski, S. Bartido, O. Borquez-Ojeda,C. Taylor, R. Yeh, V. Capacio, M. Olszewska, J. Hosey, M. Sadelain, R. J. Brentjens, I. Rivière, Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J. Immunother. 32, 169-180 (2009).
24. B. D. Cheson, J. M. Bennett, K. J. Kopecky, T. Büchner, C. L. Willman, E. H. Estey, C. A. Schiffer, H.Doehner, M. S. Tallman, T. A. Lister, F. Lo-Coco, R. Willemze, A. Biondi,W. Hiddemann, R. A. Larson, B. Löwenberg, M. A. Sanz, D. R. Head, R. Ohno, C. D. Bloomfield; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia, Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J. Clin. Oncol. 21, 4642-4649 (2003).
25. F. R. Appelbaum, D. Rosenblum, R. J. Arceci, W. L. Carroll, P. P. Breitfeld, S. J. Forman, R. A. Larson, S. J. Lee, S. B. Murphy, S. O'Brien, J. Radich, N. S. Scher, F. O. Smith, R. M. Stone,M. S. Tallman, End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood 109, 1810-1816 (2007).
26. M. Gönen, Analyzing Receiver Operating Characteristic Curves with SAS (SAS Institute, Cary, NC, 2007).
27. P. G. Steinherz, A. Redner, L. Steinherz, P. Meyers, C. Tan, G. Heller, Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol. Cancer 72, 3120-3130 (1993).
28. M. Baccarani, G. Corbelli, S. Amadori, A. Drenthe-Schonk, R. Willemze, G. Meloni, P. L. Cardozo, C. Haanen, F. Mandelli, S. Tura, Adolescent and adult acute lymphoblastic leukemia: Prognostic features and outcome of therapy. A study of 293 patients. Blood 60, 677-684 (1982).
29. V. Rodriguez, J. S. Hart, E. J. Freireich, G. P. Bodey, K. B. McCredie, J. P. Whitecar Jr., C. A. Coltman Jr., Pomp combination chemotherapy of adult acute leukemia. Cancer 32, 69-75 (1973).